



Liponex and Imasight Announce Definitive Combination Agreement

Ottawa, ON and Gatineau, QC, - March 3, 2008 - Liponex Inc (TSX:LPX), and Imasight Inc., a commercial-stage medical device company marketing an innovative, cost effective digital radiology solution, announced today that they have entered into a definitive agreement to combine their respective businesses. This transaction has been approved by the boards of directors of both companies.

The Transaction

Liponex will acquire all of the issued and outstanding shares of Imasight by way of an amalgamation between Imasight and a wholly owned subsidiary of Liponex formed for this purpose. Upon completion of the amalgamation, Imasight's shareholders will receive an aggregate of 45,313,763 Liponex common shares (without giving effect to the consolidation referenced below) and, together with Imasight optionholders and Imasight warrant holders who will exchange their securities for Liponex options and warrants, will hold securities representing an aggregate of 65% of the fully-diluted share capital of Liponex following closing.

"Our board of directors believes this business combination with Imasight maximizes the value for our shareholders," said David Evans, Chairman of Liponex Inc.

"This combination of businesses will create an integrated biotechnology company with a pipeline of new opportunities," said John Brooks, CEO of Imasight Inc. "This transaction will give us additional financial resources to advance the development and commercialization of our products."

Liponex expects to change its name and to consolidate its shares on closing in a manner to be agreed between the parties. Closing will also include the election of persons nominated by Imasight to the Board of Directors of Liponex and the appointment of John Brooks as CEO of the combined company. It is anticipated that Liponex will transfer its listing from the Toronto Stock Exchange to the TSX Venture Exchange as a Tier 2 issuer.

The agreement provides that in addition to any regulatory or exchange escrow provisions that may apply, Liponex shares received by Imasight shareholders shall be subject to a contractual escrow arrangement that will include cancellation provisions in the event of certain dilutive corporate transactions undertaken after closing and pursuant to Imasight indemnification obligations under the acquisition agreement.

A number of Imasight's largest shareholders, who collectively hold approximately 57% of Imasight's issued and outstanding shares, have each entered into support agreements with Liponex pursuant to which they have agreed to vote their shares in favour of the transaction. Liponex's CEO Bill Dickie and its CSO and largest shareholder, Dan Sparks, who collectively hold approximately 13.4% of Liponex's issued and outstanding shares, have each entered into a support

agreement with ImaSight pursuant to which they have agreed to vote their shares in favour of the transaction.

Conditions Precedent and Required Approvals

Completion of the proposed transaction, currently scheduled for April 2008, is subject to the fulfillment or waiver of various conditions precedent as more particularly set forth in the acquisition agreement, including the receipt of audited financial statements of ImaSight, all required third party consents and all required shareholder approvals and regulatory approvals, including acceptance for listing on the TSX Venture Exchange. We cannot assure you that the transaction will be completed as proposed or at all.

The approval by common shareholders of Liponex voting at an Annual and Special Meeting, expected to be held in April 2008, will be required in connection with the transaction, including the issuance of Liponex shares on the amalgamation, the name change and the consolidation. The approval of shareholders of ImaSight voting at a shareholder meeting will also be required in connection with the transaction including shareholder approval of the amalgamation.

A copy of the agreement providing for the transaction will be filed with the Canadian securities regulators. A more detailed description of the transaction structure and of the two companies will be contained in the proxy circular that will be mailed to Liponex shareholders. Once mailed, the proxy circular will be available at www.sedar.com. All shareholders are urged to read the proxy circular once it is available. Investors are cautioned that, except as disclosed in the proxy circular to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Liponex should be considered highly speculative.

About ImaSight and its Digital Radiography System

ImaSight markets its patented digital x-ray sensor at a price affordable to veterinarians and chiropractors. Its hospital grade sensor has been approved for sale by Health Canada. Further information can be found at www.imasight.com

About Liponex and CRD5

Liponex is a Biopharmaceutical development company developing natural source products for the treatment of cholesterol and metabolic disease. CRD5, its lead product, has undergone a number of human clinical trials under approval of Health Canada's Natural Health Products Directorate with a primary goal of increasing HDL "good cholesterol".

This news release contains certain "forward-looking statements" and "forward-looking information" which may include but is not limited to statements in respect of Liponex's and ImaSight's future financial position or operations. Words like "believe", "intend", "may", "expect", "anticipate", "plan", "should" and other similar expressions are forward-looking statements that involve a number of risks and uncertainties. By their nature, forward-looking statements involve numerous factors, assumptions and estimates. Some but not all of the factors that could cause actual results to differ materially from those projected in our forward-looking statements include among others:

- *failure to receive required transaction approvals from Liponex's and ImaSight's shareholders;*
- *failure to receive necessary stock exchange listing approvals and/or necessary approvals of the Canadian regulatory authorities;*

- *the ability of Liponex and ImaSight to satisfy all of the closing conditions to complete the transaction;*
- *market acceptance of ImaSight's technologies and products assuming the successful completion of the transaction;*
- *ImaSight's (and, assuming the approval of the arrangement, the combined company's) ability to obtain financing in the future, financial and technical resources relative to those of its competitors, ability to enforce its intellectual property rights and protect its proprietary technologies; and*
- *other risk factors identified from time to time in Liponex's (and, assuming the approval of the arrangement, the combined company's) securities regulatory filings.*

For a further description of the principal risks affecting Liponex, see Liponex's regulatory filings at www.sedar.com. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward looking statements. Although Liponex and ImaSight have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and neither Liponex nor ImaSight undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof.

The TSX does not accept responsibility for the adequacy or accuracy of this release.

For further information:

Liponex Inc.:

Investor Relations
Michael Moore
The Equicom Group Inc.
(416) 815-0700 ext. 241
mmoore@equicomgroup.com

ImaSight Inc.:

John Brooks, CEO
(819) 777-7979 ext. 223
jbrooks@imasight.com